The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Dynamic follow-up of SMM can identify patients at high risk of progression
Hareth Nahi, MD, PhD, of the Karolinska Institutet, Stockholm, Sweden, explains how dynamic follow-up of patients with smoldering multiple myeloma (SMM) can be used to identify patients at high risk of disease progression. SMM is usually asymptomatic and is only measured at diagnosis, however, as myeloma is a dynamic disease, Dr Nahi suggests that the monitoring of SMM needs to be increased over time using parameters such as the level of plasma monoclonal proteins and free light chains. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
